Loading...
•
Sep 30, 2024
Bio-Techne Q1 2025 Earnings Report
Bio-Techne's first quarter of fiscal year 2025 was marked by revenue growth and adjusted EPS increase.
Key Takeaways
Bio-Techne reported a 5% increase in revenue to $289.5 million, with organic revenue growth of 4%. GAAP EPS was $0.21, while adjusted EPS increased to $0.42. The Diagnostics & Spatial Biology segment drove growth with a 14% organic increase.
First quarter organic revenue increased by 4% (5% reported) to $289.5 million.
GAAP earnings per share (EPS) was $0.21 versus $0.31 one year ago. Adjusted EPS was $0.42 compared to $0.41 one year ago.
The Diagnostics & Spatial Biology segment saw 14% organic growth.
There was continued uptake of cell and gene therapy workflow solutions, including growth in GMP reagent offerings.
Bio-Techne
Bio-Techne
Bio-Techne Revenue by Segment
Revenue by Segment
Protein Sciences Revenue
CapyFin.comDiagnostics & Spatial Bio Revenue
CapyFin.com Forward Guidance
No specific forward guidance was provided in the release.
Revenue & Expenses
Visualization of income flow from segment revenue to net income